Telix Granted FDA Fast Track Designation for Prostate Cancer Imaging Program

Telix Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its BiPASS program. This program is evaluating 68Ga-PSMA-PET imaging in combination with MRI for the detection of prostate cancer prior to biopsy, with the goal of accelerating patient access to an imaging-first diagnostic approach.